February 22, 2024
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is pleased to announce that it has received the first patient sample for its Research studies done with patients to evaluate new treatments or new ways of combining and administering existing treatments. By testing new drugs or combinations of drugs, each study is designed to find better ways to treat the disease, as well as improve quality of life and answer scientific and clinical questions. The overall goal of conducting clinical trials is to improve patient care and outcomes. monitoring multiple myeloma (“MM”) When a disease or physical ailment's course worsens, grows or spreads. in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General[…]Learn more
February 21, 2024
High BMI in Early Adulthood Increases Multiple Myeloma Risk Among Black Women
High body mass index (BMI) in early adulthood associated with increased risk for multiple myeloma (MM) among Black women, according to results published in the British Journal of A term for diseases in which malignant cells divide without control. Cancer cells can invade nearby tissues and spread through the bloodstream and lymphatic system to other parts of the body.. The The number of new cases of a disease diagnosed each year. of MM is more than 2-times higher for Black persons. Male gender, age, and African ancestry are established MM risk[…]Learn more
February 21, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor survival. Novel therapies and combinations are therefore required to improve outcomes. B The basic unit of any living organism. maturation Foreign substance that can be recognized by cells of the immune system leading to the production of protective antibodies. (BCMA)-targeted biologics have emerged as an important new area of therapeutics for relapsed[…]Learn more
February 21, 2024
Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update
In Canada, more than 2 million people live with Reduction in bone density typically associated with old age. Diffuse involvement of bones with myeloma produces what looks like osteoporosis on X-ray and bone density measurement., a disease that increases the risk for fractures, which result in excess mortality and morbidity, decreased quality of life and loss of autonomy. This guideline update is intended to assist Canadian health care professionals in the delivery of care to[…]Learn more
February 21, 2024
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting
The International Myeloma Foundation’s Black Swan Research Initiative® (BSRI) proudly showcased four oral and two poster abstracts from the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA which took place from December 9-12, 2023. Read more… […]Learn more
February 21, 2024
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial
Pieter Sonneveld, MD, PhD (Erasmus MC Cancer Institute — Rotterdam, Netherlands) discusses the effectiveness of Daratumumab (DARA SC) in combination with bortezomib, lenalidomide, and A powerful corticosteroid given alone or with other chemotherapy drugs. (VRd) as induction/consolidation therapy as opposed to VRd alone in myeloma patients eligible for autologous stem cell Stem cells are used to rescue to patient' s blood-forming potential following high dose chemotherapy and/or radiation treatment. Transplant is not a treatment, but a method of support to make high dose treatment possible.
• Bone marrow transplantation – This term refers to the process of collecting stem cells from the bone marrow and infusing them into a patient. This term is used less freuently today in myeloma as stem cells are now collected from the peripheral or circulating blood.
• Peripheral blood stem cell transplantation – Doctors remove healthy stem cells from a patient's circulating blood system (not from the bone marrow) and store them before the patient receives high-dose chemotherapy and possibly radiation therapy to destroy the cancer cells. The stem cells are then returned to the patient, where they can produce new blood cells to replace cells destroyed by the treatment.
• Allogeneic – The infusion of bone marrow or stem cells from one individual (donor) to another (recipient). A patient receives bone marrow or stem cells from a compatible, though not genetically identical, donor.
• Autologous – A procedure in which stem cells are removed from a patient's blood and then are given back to the patient following intensive treatment.
• Matched unrelated donor transplants (MUDs) – Refers to stem cell transplantation procedures in which the patient and the stem cells are genetically matched but are not from family members. This procedure is not recommended for myeloma patients because it carries an unacceptably high mortality rate.
• Syngeneic – The infusion of bone marrow or stem cells from one identical twin into another.
. Watch the video now… […]
Myeloma Canada updates
February 22, 2024
IMAGINE CANADA Organization Spotlight: Myeloma Canada
Established in 2005, Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. Their mission is to improve the lives of those affected by this disease by empowering our community through awareness, education, and advocacy programs, and by supporting Involving direct observation of a patient. research to find[…]Learn more
February 20, 2024
2023 Dr Andrew R Belch MEET Grant for young myeloma investigators
A total of 8 MEET Grants were awarded in 2023. Click on the links below to view video presentations from select winners and their important work. Dory Abelman: Cell-Free The substance of heredity; a large molecule that carries the genetic information that cells need to replicate and to produce proteins. from Blood or Spongy tissue that is found inside your bones. It is soft, fatty and full of blood vessels. Your bone marrow is where most of the blood cells in your body are made. as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma “I am profoundly[…]Learn more
February 4, 2024
A new multiple myeloma trial assessing the duration of treatment injections has opened in Canada.
The CCTG MY13 trial is a phase III non-inferiority randomized controlled trial of fixed duration versus continuous daratumumab among transplant in eligible older adults with newly diagnosed multiple myeloma. There is little scientific evidence around the effective timing of injectable treatments for multiple myeloma. These patients receive treatment with three medicines[…]Learn more
December 15, 2023
Opinion: CAR T-Cell THERAcell therapy delays jeopardize lives of Canadians with blood cancer
Myeloma Canada is a member of thecancercollaborative (Colab) a cancer collaborative and patient-driven think-tank dedicated to bridging science, policy, and advocacy to accelerate policy change and make a meaningful contribution to cancer care. Along with other members, we signed Colab’s opinion letter for a multi-stakeholder approach to develop solutions that[…]Learn more
October 24, 2023
UCalgary and AHS researchers discover how multiple myeloma cells become resistant to immunotherapy
Lisa Mack is cancer free, for now, and looking forward to her 75th birthday in December. She was a participant in a clinical trial at the Tom Baker Cancer Centre (TBCC) that has helped University of Calgary and Alberta Health Services researchers better understand why multiple myeloma (MM) cells become[…]Learn more
October 20, 2023
Ontario, Nova Scotia and British Columbia, rejoice! Selinexor is now funded in your province!
We are thrilled to inform you that, effective September 7th, XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, is now funded in Ontario, since September 7, as wells as in Nova Scotia[…]Learn more